Exact Sciences (Nasdaq:EXAS) announced that it launched its OncoExTra cancer therapy selection test in the U.S.
OncoExTra is a next-generation sequencing, comprehensive DNA- and RNA-based genomic test. Madison, Wisconsin-based Exact Sciences designed it to provide doctors and patients a complete molecular picture of the patient’s cancer. The test provides reliable and actionable results personalized to each patient.
Comprehensive genomic profiling (CGP) helps patients understand their cancer and guide treatment. Personalized medicine powered by CGP helps oncologists understand the unique biology of each patient’s tumor. Oncologists can then prescribe treatments determined to offer the best outcomes, according to a news release.
“The OncoExTra test substantially enhances our ability to characterize and understand solid tumors, giving our patients the best chance at treating their cancer successfully,” said Dr. Stephen Gruber, VP of the City of Hope National Medical Center and Director, Center for Precision Medicine at City of Hope. “With this test, I have a much better picture of my patient’s cancer, allowing me to prescribe the most effective treatment for their specific solid tumor.”
How the Exact Sciences OncoExTra test works
The test uses NGS to assess a tumor’s RNA and DNA. It provides information that informs treatment decisions and uncovers variants possibly missed by only evaluating DNA.
OncoExTra profiles the entire exome and transcriptome across approximately 20,000 genes. It uses matched tumor-normal sequencing to limit false positives.
Exact Sciences said Medicare covers its OncoExTra test and doctors can order the test for all advanced solid tumors. It also includes information on targetable mutations and fusions, as well as immuno-oncology signatures and clinical trial options.
“Exact Sciences continues to build its leadership in cancer diagnostics by offering innovative tests addressing clinical needs at every step of patient cancer care,” said Kevin Conroy, chair and CEO of Exact Sciences. “We are proud to add OncoExTra to our growing portfolio of cancer solutions across the cancer-care continuum, and deliver new levels of tumor-specific information and insights to doctors and patients that guide vital treatment decisions to achieve the best outcomes.”